Authors

Latest:

Dr. Sznol on the Significance of the Relatlimab/Nivolumab Approval in Metastatic Melanoma

Mario Sznol, MD, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.

Marissa Murtaugh

Latest:

Poster Session Highlights: 12th International Lung Cancer Congress

A highlight of 3 poster sessions from the 12th International Lung Cancer Congress on August 12, 2011 in Carlsbad, CA.

Mark A. Morgan, MD

Latest:

Dr. Morgan on Bulk Reduction Surgery in Ovarian Cancer

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.

Mark A. Rubin, MD

Latest:

Dr. Rubin on Advantages With Whole-Exome Sequencing

Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

Mark A. Schroeder, MD

Latest:

Dr. Schroeder on the Importance of JAK Inhibition in GVHD

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

Mark A. Socinski

Latest:

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Mark A. Socinski, MD

Mark Socinski, MD, is a medical oncologist and the executive medical director of the AdventHealth Cancer Institute in Orlando, Florida.

Latest:

The Role of DNA & RNA in Comprehensive Genomic Profiling

Experts discuss the critical importance of including RNA sequencing in comprehensive biomarker testing for non-small cell lung cancer (NSCLC). They highlight that while DNA-based NGS is foundational, it is insufficient for reliably detecting key gene fusions like RET and ROS1

Mark A. Socinski, MD, Advent Health Cancer Institute

Latest:

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Mark A. Socinski, MD, AdventHealth Cancer Institute

Latest:

Defining Financial Toxicity in Cancer Care

Opening their discussion on the cost of cancer care, expert oncologists define financial toxicity and identify some of its most prevalent contributors.

Mark A. Socinski, MD, Florida Hospital Cancer Institute

Mark A. Socinski, MD, Pittsburgh&nbsp

Mark A. Socinski, MD, University of Pitt

Mark A. Socinski, MD, University of Pittsburgh

Mark A. Socinski, MD, University of Pittsburgh Medical Center

Mark A. Socinski, MD, UPMC

Mark Agulnik, MD, Feinberg School of Medicine

Mark Agulnik, MD, Northwestern University Feinberg School of Medicine

Mark Anderson

Latest:

Overcoming the Hurdles to EHR Adoption

A survey conducted by the Institute for Health Policy between late 2007 and early 2008 found that only 4% of physicians are using a fully functional EHR.

Mark B. Juckett, MD

Latest:

Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AML

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Mark Ball, MD

Latest:

Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.